Clinical trials: Pancreatic Ductal Adenocarcinoma
Non-Small Cell Lung Cancer, Ovarian Cancer
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express…
- Conditions
- Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04025216
- Testing
- CART-TnMUC1, Cyclophosphamide, Fludarabine
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- Kite, A Gilead Company
Neuroendocrine Tumors
Capecitabine and Temozolomide for Neuroendocrine Cancers
This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive, differentiated, metastatic neuroendocrine tumors (NET).
- Trial name
- NCT00869050
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Columbia University
Pancreatic Ductal Adenocarcinoma
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and…
- Trial name
- NCT05257993
- Testing
- JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
- Where
- 4 sites in South Korea
- Volunteers
- 71 people
- Sponsor
- Onconic Therapeutics Inc.
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma
This will be a single-arm, multi-center, open-label phase 1 study. The standard 3+3 design will be used to determine the maximum tolerated dose (MTD) from 4 possible dose levels of Eryaspase in combination with mFOLFIRINOX.
- Trial name
- NCT04292743
- Testing
- Eryaspase, FOLFIRINOX
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Georgetown University
Pancreas Cancer, Pancreatic Adenocarcinoma
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma…
- Conditions
- Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- SEPION (NCT04257448)
- Testing
- Romidepsin, Azacitidine, nab-Paclitaxel
- Where
- 9 sites in Germany
- Volunteers
- 75 people
- Sponsor
- GWT-TUD GmbH
Pancreatic Ductal Adenocarcinoma
NGS and TME for Evidence-based Treatment of Pancreatic Cancer
The tumor tissue of patients with pancreatic cancer will be submitted to next-generation sequencing (NGS) and these data will be evaluated with an oncology treatment decision support (TDS) software tool that is a medicinal…
- Trial name
- PePaCaKa-01 (NCT02767700)
- Testing
- NGS
- Volunteers
- 39 people
- Sponsor
- Karolinska University Hospital
Advanced Pancreatic Ductal Adenocarcinoma
KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.
This study is a multicenter, randomized, double-Blind Phase III Study to compare the clinical efficacy and safety of KN046 plus gemcitabine and nab-paclitaxel versus placebo plus gemcitabine and nab-paclitaxel in subjects with…
- Trial name
- NCT05149326
- Testing
- KN046
- Where
- 65 sites in China
- Volunteers
- 408 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Pancreatic Ductal Adenocarcinoma
A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma
This study has stopped recruitment. Adults with advanced pancreatic cancer participate in this study. The study tests a type of immunotherapy.
- Trial name
- NCT05846516
- Testing
- VSV-GP154, ATP150, ATP152
- Where
- 21 sites in United States, Germany and 2 more
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Skeletal Muscle Radiodensity, Myosteatosis
Prognostic Value of Myosteatosis and Creatinine-to-cystatin C Ratio in Patients With Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a 5-year survival rate as low as 6%. It causes body composition changes and many patients develop muscle loss with disease progression.
- Conditions
- Skeletal Muscle Radiodensity, Myosteatosis, Scr/CysC Ratio, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05584852
- Where
- China
- Volunteers
- 240 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- MOONRAY-01 (NCT06586515)
- Testing
- LY3962673, Cetuximab, Gemcitabine
- Where
- 52 sites in United States, Canada and 7 more
- Volunteers
- 630 people
- Sponsor
- Eli Lilly and Company
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are…
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT07573215
- Testing
- daraxonrasib
- Where
- 257 sites in United States, Puerto Rico
- Sponsor
- Revolution Medicines, Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This is an investigator-initiated, open-label, single-arm, phase II trial evaluating the efficacy and safety of serplulimab (an anti-PD-1 monoclonal antibody) plus bevacizumab, combined with either FOLFIRINOX or NALIRIFOX…
- Trial name
- NCT07733050
- Testing
- Serplulimab and Bevacizumab injection, FOLFIRINOX/NALIRIFOX, S-1
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Shanghai General Hospital, China